FUNDACION CTIC CENTRO DE TRATAMIENTO E INVESTIGACION SOBRE CANCER LUIS CARLOS SARMIENTO ANGULO (Site 0600)

The trials here

What the 2 trials at this site are about, from their registry records.

Conditions

• Lung cancer2 trials

Phase

• Phase 32 trials

Status

• Active, not recruiting1 trial
• Recruiting1 trial

Lead sponsor

• Merck Sharp & Dohme LLC2 trials

Running trials

• Active, not recruiting

  Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

  NCT06305754· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

  NCT06170788· Phase 3· Merck Sharp & Dohme LLC· Source

  Contact: Study Coordinator

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer1 recruiting